Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tillotts Pharma AG

Division of Zeria Pharmaceutical Co. Ltd.

Latest From Tillotts Pharma AG

Deal Watch: Pfizer, Allergan Continue Deal-Making Ahead Of Merger

Novo Nordisk aligns with Xoma to develop monoclonal antibodies that could up-regulate the insulin receptor, and also signs an R&D pact with Ablynx. Takeda and Teva agree to joint venture in Japan built around the Japanese pharma's mature products.

BioPharmaceutical Deals

Biopharma Quarterly Dealmaking Statistics, Q3 2015

Biopharma financing totaled $9.7 billion, almost half from follow-on public offerings; there was big consolidation in the generics and health services industries. AstraZeneca signed a dozen partnerships, many of which focused on oncology.

BioPharmaceutical Deals

Diabetes sales lead AstraZeneca's first half fight back

"Genuinely driven by product sales" was how some analysts saw AstraZeneca's better-than-expected performance in the second quarter.

Metabolic Disorders Dermatology

AstraZeneca divests troublesome thyroid cancer drug

In the latest in a series of divestments of non-core assets by AstraZeneca, it is to sell Caprelsa (vandetanib) – a rare disease medicine – to Sanofi's Genzyme for up to $300m.

Gastrointestinal Japan
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Zeria Pharmaceutical Co. Ltd.
  • Senior Management
  • Thomas Tóth von Kiskér, CEO
    Mattias Norrman, COO
    Johannes Spleiss, CSO
    Dirk Reckert, Chief Bus. Dev. Off.
  • Contact Info
  • Tillotts Pharma AG
    Phone: (41) 61 935 26 26
    Baslerstrasse 15
    Rheinfelden, CH-4310